Immix Biopharma Inc(IMMX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 9 at 4:01 PM ET (Korea 11/10 06:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.88 | Insider Own | 17.71% | Shs Outstand | 71.5M | Perf Week | 18.04% |
| Market Cap | 0.71B | Forward P/E | - | EPS next Y | -31.39% | Insider Trans | - | Shs Float | 68.2M | Perf Month | -9.41% |
| Enterprise Value | 0.48B | PEG | - | EPS next Q | -0.19 | Inst Own | 71.65% | Short Float | 15.7% | Perf Quarter | -25.41% |
| Income | -0.04B | P/S | - | EPS this Y | 18.98% | Inst Trans | 56.49% | Short Ratio | 7.06 | Perf Half Y | -13.61% |
| Sales | 0.00B | P/B | 2.68 | EPS next 5Y | 9.33% | ROA | -31.34% | Short Interest | 10.71M | Perf YTD | 63.86% |
| Book/sh | 3.2 | P/C | 3.06 | EPS past 3/5Y | -12.81% -43.32% | ROE | -34.18% | 52W High | -43.25% ($15.10) | Perf Year | 172.06% |
| Cash/sh | 2.8 | P/FCF | - | Sales past 3/5Y | - | ROIC | -17.37% | 52W Low | 196.53% ($2.89) | Perf 3Y | 131% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.21% | Gross Margin | - | Volatility(W/M) | 11.01% 7.76% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 25.13 | EPS Q/Q | 17.97% | Profit Margin | - | RSI (14) | 48.82 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 25.13 | Sales Q/Q | - | SMA20 | 5.37% ($8.13) | Beta | 0.29 | Target Price | $24.05 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -16.6% ($10.28) | Rel Volume | 0.84 | Prev Close | $8.06 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.51% - | SMA200 | -10.43% ($9.57) | Avg Volume(3M) | 1.52M | Price | $8.57 |
| IPO | 2021/12/16 | Option/Short | Yes/Yes | Trades | 9935 | Volume | 1,269,941 | Change | 6.33% |
🧬 Emix BioPharma is a US clinical-stage biotech company developing BCMA-targeting cell therapies, including NXC-201. The company focuses on rare hematologic diseases such as light chain amyloidosis and multiple myeloma, pursuing differentiated treatment options in areas with high unmet medical needs through its autologous CAR-T cell therapy platform and NEXICART clinical program.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
IMMX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +19.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +131.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 71.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #188 of 597 in the industry
Based on market cap of $710M.
NVCT#186 Nuvectis Pharma Inc $723M PER - 
ZVRA#187 Zevra Therapeutics Inc $722M PER 10.2 IMMX#188 Immix Biopharma Inc $710M PER - 
AVBP#189 ArriVent BioPharma Inc $698M PER - 
ACHV#190 AchieveRx Quit Co $698M PER - 
FAQ
What kind of company is IMMX?
IMMX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMMX?
The market cap of IMMX is approximately $710M, ranking 2,852 within its sector.
What is the 52-week high and low for IMMX?
IMMX has recorded a 52-week high of $15.10 and a low of $2.89.
